Ambea (AMBEA) Q2 2025 earnings summary

Executive summary

• Net sales increased 16% year-over-year in Q2 2025 to SEK 4,088 million, driven by 13% acquired growth and 5% organic growth, mainly from the Validia acquisition.

• Adjusted EBITA rose 15% to SEK 311 million, with a margin of 7.6%; all financial targets for growth, profitability, and leverage were achieved for the first time.

• Major acquisitions included Validia in Finland and AvAsta in Sweden, expanding care capacity and geographic reach.

• Employee engagement remains high, with an ENPS of +26, reflecting a strong workplace culture.

• Sustainability initiatives advanced, including textile recycling and digital health support for employees.

Financial highlights

• Q2 2025 net sales: SEK 4,088 million (up 16% year-over-year); adjusted EBITA: SEK 311 million (margin 7.6%).

• Adjusted EPS continued strong growth, with a 39.3% CAGR from 2023 to 2025.

• Free cash flow Q2: SEK 425 million, negatively affected by non-recurring items; operating cash flow remained stable.

• Net debt increased due to strategic acquisitions, standing at SEK 3,545 million at 30 June 2025.

• Share buybacks and dividends distributed, with SEK 365 million spent on buybacks and SEK 185 million on dividends.

Outlook and guidance

• Continued solid growth expected, supported by acquisitions and organic expansion, with further pipeline and capacity additions planned.

• Margin stabilization anticipated in Nytida and Altiden, with normalized demand and margin discipline in Stendi.

• Integration of Validia is on track, with full completion expected in Q1 2026.

• No risk of sales decline seen in Stendi; demand has normalized at a strong level.

• Continued active M&A expected, particularly in Finland and Denmark.